BACKGROUND: Asbestos is a carcinogen linked to malignant mesothelioma (MM) and lung cancer. Some gene aberrations related to asbestos exposure are recognized, but many associated mutations remain obscure. We performed exome sequencing to determine the association of previously known mutations (driver gene mutations) with asbestos and to identify novel mutations related to asbestos exposure in lung adenocarcinoma (LAC) and MM. METHODS: Exome sequencing was performed on DNA from 47 tumor tissues of MM (21) and LAC (26) patients, 27 of whom had been asbestos-exposed (18 MM, 9 LAC). In addition, 9 normal lung/blood samples of LAC were sequenced. Novel mutations identified from exome data were validated by amplicon-based deep sequencing. Driver gene mutations in BRAF, EGFR, ERBB2, HRAS, KRAS, MET, NRAS, PIK3CA, STK11, and ephrin receptor genes (EPHA1-8, 10 and EPHB1-4, 6) were studied for both LAC and MM, and in BAP1, CUL1, CDKN2A, and NF2 for MM. RESULTS: In asbestos-exposed MM patients, previously non-described NF2 frameshift mutation (one) and BAP1 mutations (four) were detected. Exome data mining revealed some genes potentially associated with asbestos exposure, such as MRPL1 and SDK1. BAP1 and COPG1 mutations were seen exclusively in MM. Pathogenic KRAS mutations were common in LAC patients (42 %), both in non-exposed (n = 5) and exposed patients (n = 6). Pathogenic BRAF mutations were found in two LACs. CONCLUSION: BAP1 mutations occurred in asbestos-exposed MM. MRPL1, SDK1, SEMA5B, and INPP4A could possibly serve as candidate genes for alterations associated with asbestos exposure. KRAS mutations in LAC were not associated with asbestos exposure.
BACKGROUND:Asbestos is a carcinogen linked to malignant mesothelioma (MM) and lung cancer. Some gene aberrations related to asbestos exposure are recognized, but many associated mutations remain obscure. We performed exome sequencing to determine the association of previously known mutations (driver gene mutations) with asbestos and to identify novel mutations related to asbestos exposure in lung adenocarcinoma (LAC) and MM. METHODS: Exome sequencing was performed on DNA from 47 tumor tissues of MM (21) and LAC (26) patients, 27 of whom had been asbestos-exposed (18 MM, 9 LAC). In addition, 9 normal lung/blood samples of LAC were sequenced. Novel mutations identified from exome data were validated by amplicon-based deep sequencing. Driver gene mutations in BRAF, EGFR, ERBB2, HRAS, KRAS, MET, NRAS, PIK3CA, STK11, and ephrin receptor genes (EPHA1-8, 10 and EPHB1-4, 6) were studied for both LAC and MM, and in BAP1, CUL1, CDKN2A, and NF2 for MM. RESULTS: In asbestos-exposed MM patients, previously non-described NF2 frameshift mutation (one) and BAP1 mutations (four) were detected. Exome data mining revealed some genes potentially associated with asbestos exposure, such as MRPL1 and SDK1. BAP1 and COPG1 mutations were seen exclusively in MM. Pathogenic KRAS mutations were common in LAC patients (42 %), both in non-exposed (n = 5) and exposed patients (n = 6). Pathogenic BRAF mutations were found in two LACs. CONCLUSION:BAP1 mutations occurred in asbestos-exposed MM. MRPL1, SDK1, SEMA5B, and INPP4A could possibly serve as candidate genes for alterations associated with asbestos exposure. KRAS mutations in LAC were not associated with asbestos exposure.
Authors: Matthew Bott; Marie Brevet; Barry S Taylor; Shigeki Shimizu; Tatsuo Ito; Lu Wang; Jenette Creaney; Richard A Lake; Maureen F Zakowski; Boris Reva; Chris Sander; Robert Delsite; Simon Powell; Qin Zhou; Ronglai Shen; Adam Olshen; Valerie Rusch; Marc Ladanyi Journal: Nat Genet Date: 2011-06-05 Impact factor: 38.330
Authors: Gemma Cadby; Sutapa Mukherjee; A W Bill Musk; Alison Reid; Mike Garlepp; Ian Dick; Cleo Robinson; Jennie Hui; Giovanni Fiorito; Simonetta Guarrera; John Beilby; Phillip E Melton; Eric K Moses; Donatella Ugolini; Dario Mirabelli; Stefano Bonassi; Corrado Magnani; Irma Dianzani; Giuseppe Matullo; Bruce Robinson; Jenette Creaney; Lyle J Palmer Journal: Lung Cancer Date: 2013-07-01 Impact factor: 5.705
Authors: Mohamed Guled; Leo Lahti; Pamela M Lindholm; Kaisa Salmenkivi; Izhar Bagwan; Andrew G Nicholson; Sakari Knuutila Journal: Genes Chromosomes Cancer Date: 2009-07 Impact factor: 5.006
Authors: Katja Tuononen; Satu Mäki-Nevala; Virinder Kaur Sarhadi; Aino Wirtanen; Mikko Rönty; Kaisa Salmenkivi; Jenny M Andrews; Aino I Telaranta-Keerie; Sari Hannula; Sonja Lagström; Pekka Ellonen; Aija Knuuttila; Sakari Knuutila Journal: Genes Chromosomes Cancer Date: 2013-01-30 Impact factor: 5.006
Authors: Sandra Hakim; Micka C Bertucci; Sarah E Conduit; David L Vuong; Christina A Mitchell Journal: Curr Top Microbiol Immunol Date: 2012 Impact factor: 4.291
Authors: Yin P Hung; Fei Dong; Matthew Torre; Christopher P Crum; Raphael Bueno; Lucian R Chirieac Journal: Mod Pathol Date: 2020-06-05 Impact factor: 7.842
Authors: Adam P Sage; Victor D Martinez; Brenda C Minatel; Michelle E Pewarchuk; Erin A Marshall; Gavin M MacAulay; Roland Hubaux; Dustin D Pearson; Aaron A Goodarzi; Graham Dellaire; Wan L Lam Journal: High Throughput Date: 2018-07-27
Authors: Jessie Qiaoyi Liang; Narcissus Teoh; Lixia Xu; Sharon Pok; Xiangchun Li; Eagle S H Chu; Jonathan Chiu; Ling Dong; Evi Arfianti; W Geoffrey Haigh; Matthew M Yeh; George N Ioannou; Joseph J Y Sung; Geoffrey Farrell; Jun Yu Journal: Nat Commun Date: 2018-10-26 Impact factor: 14.919